Human vascular smooth muscle cells. Target for and source of tumor necrosis factor.
Open Access
- 1 January 1989
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 142 (1) , 100-109
- https://doi.org/10.4049/jimmunol.142.1.100
Abstract
TNF-alpha (also known as cachectin) may produce many of its important effects in vivo by actions on blood vessels. Endothelial cells are well known to respond to TNF-alpha. We investigated whether vascular smooth muscle cells (SMC), the most abundant cell type in most vessels, also respond to TNF-alpha and the related cytokine lymphotoxin (TNF-beta). Both human rTNF-alpha and beta (0.1 to 100 ng/ml) induced transient accumulation of IL-1 mRNA by adult human vascular SMC that peaked between 1 and 4 h. The inhibitor of RNA synthesis actinomycin D (1 microgram/ml) blocked the induction of IL-1 mRNA, whereas inhibition of protein synthesis with cycloheximide (1 microgram/ml) resulted in a marked "superinduction" of both IL-1 alpha and IL-1 beta mRNA species. TNF-alpha treatment also increased intracellular biologically active IL-1 and subsequent release of IL-1 activity from SMC. Metabolic labeling and immunoprecipitation with specific antibodies demonstrated de novo synthesis of IL-1 alpha and IL-1 beta precursors in TNF-treated or lymphotoxin-treated SMC. TNF-alpha also activated other SMC functions including the concentration-dependent release of PGE2 from SMC, and time-dependent induction of the gene for (2'-5')-oligoadenylate synthetase, an enzyme thought to mediate the anti-viral and anti-proliferative actions of IFN. We also explored whether SMC, which both produce and respond to IL-1, might also express either of the TNF genes. Bacterial LPS (10 micrograms/ml) caused slight accumulation of TNF-alpha transcripts. Incubation of SMC for 4 h with inhibitors of protein synthesis alone caused little or no elevation of TNF-alpha mRNA, but simultaneous addition of LPS ("superinduction" conditions) induced large amounts of TNF-alpha (but not TNF-beta) mRNA. Cells treated with anisomycin (1 microgram/ml) and LPS, then washed to remove this reversible inhibitor of protein synthesis, released TNF-alpha into the medium, as assessed by the L929 cytotoxicity assay and by metabolic labeling and immunoprecipitation. Thus, SMC both respond to both TNF and lymphotoxin and can produce TNF-alpha, a cytokine with numerous effects on vascular cells of potential significance in the pathophysiology of septic shock and other inflammatory conditions.This publication has 32 references indexed in Scilit:
- Recombinant human interleukin 1 alpha: purification and biological characterization.The Journal of Immunology, 1986
- RECOMBINANT TUMOR-NECROSIS-FACTOR AND IMMUNE INTERFERON ACT SINGLY AND IN COMBINATION TO REORGANIZE HUMAN VASCULAR ENDOTHELIAL-CELL MONOLAYERS1986
- Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells.The Journal of Immunology, 1986
- Modulation of endothelial cell hemostatic properties by tumor necrosis factor.The Journal of Experimental Medicine, 1986
- Characteristics of lipopolysaccharide interaction with human peripheral-blood monocytesBiochemical Journal, 1985
- Structure of two forms of the interferon-induced (2′-5′) oligo A synthetase of human cells based on cDNAs and gene sequences.The EMBO Journal, 1985
- Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line.Journal of Biological Chemistry, 1985
- Comparison of in vitro cell cytotoxic assays for tumor necrosis factorJournal of Immunological Methods, 1984
- Regulation of tubulin and actin mRNA production in rat brain: expression of a new beta-tubulin mRNA with development.Molecular and Cellular Biology, 1983
- Isolation of biologically active ribonucleic acid from sources enriched in ribonucleaseBiochemistry, 1979